NASDAQ: IMRXImmuneering Corp Stock
$1.90-0.06 (-3.06%)
Updated Jun 13, 2025
Immuneering shares are trading higher... find out Why IMRX Price Moved with a free WallStreetZen account
Why Price MovedIMRX Price
$1.90
Fair Value Price
$1.07
Market Cap
$68.37M
52 Week Low
$1.00
52 Week High
$3.83
P/E
-0.96x
P/B
1.63x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$61.77M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$54M
Beta
1.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IMRX Overview
Immuneering Corporation is a a biopharma focused on the oncology and neuroscience sectors. The company's oncology programs is developing treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Its lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Immuneering was incorporated in 2008 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IMRX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IMRX
Ranked#345 of 464
Ranked#345 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important IMRX news, forecast changes, insider trades & much more!
IMRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMRX ($1.90) is overvalued by 78.12% relative to our estimate of its Fair Value price of $1.07 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMRX ($1.90) is not significantly undervalued (78.12%) relative to our estimate of its Fair Value price of $1.07 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMRX due diligence checks available for Premium users.
Valuation
IMRX fair value
Fair Value of IMRX stock based on Discounted Cash Flow (DCF)
Price
$1.90
Fair Value
$1.07
Overvalued by
78.12%
IMRX ($1.90) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMRX ($1.90) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.96x
Industry
-108.97x
Market
31.36x
IMRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.63x
Industry
4.66x
IMRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.0M
Profit Margin
0%
IMRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$50.7M
Liabilities
$8.8M
Debt to equity
0.21
IMRX's short-term assets ($38.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMRX's short-term assets ($38.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.1M
Investing
-$8.9k
Financing
$13.8M
IMRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMRX vs Biotech Stocks
Immuneering Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.